UPDATE: Acasti Pharma Q4 Adj EPS $(0.11), Inline
Portfolio Pulse from Benzinga Newsdesk
Acasti Pharma (NASDAQ:ACST) reported Q4 adjusted EPS of $(0.11), in line with analyst consensus estimates, representing a 175% decrease from $(0.04) per share in the same period last year.
June 23, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Acasti Pharma's Q4 earnings report showed a 175% decrease in adjusted EPS compared to last year, meeting analyst expectations.
Acasti Pharma's Q4 earnings report showed a significant decrease in adjusted EPS compared to the same period last year. However, the results were in line with analyst expectations, which may not have a significant short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100